United Therapeutics (NASDAQ:UTHR) had its target price hoisted by analysts at Oppenheimer to $180.00 in a research report issued to clients and investors on Friday. The brokerage currently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price objective suggests a potential upside of 20.17% from the company’s current price.
Other analysts also recently issued research reports about the stock. Zacks Investment Research downgraded shares of United Therapeutics from a “hold” rating to a “strong sell” rating in a report on Tuesday, October 3rd. TheStreet downgraded shares of United Therapeutics from a “b-” rating to a “c” rating in a report on Friday, September 29th. Cowen reaffirmed a “hold” rating and set a $129.00 price target on shares of United Therapeutics in a report on Friday, October 27th. HC Wainwright reaffirmed a “hold” rating and set a $95.00 price target on shares of United Therapeutics in a report on Thursday, October 26th. Finally, Wedbush reaffirmed an “outperform” rating and set a $232.00 price target (up previously from $213.00) on shares of United Therapeutics in a report on Wednesday, December 27th. Three analysts have rated the stock with a sell rating, eight have assigned a hold rating, two have given a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $138.50.
Shares of United Therapeutics (UTHR) traded down $0.04 during trading hours on Friday, hitting $149.79. 365,608 shares of the company’s stock were exchanged, compared to its average volume of 380,777. United Therapeutics has a 1 year low of $112.01 and a 1 year high of $169.89. The firm has a market cap of $6,470.00, a price-to-earnings ratio of 13.21 and a beta of 1.41.
United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $4.01 by $2.26. United Therapeutics had a net margin of 30.50% and a return on equity of 26.24%. The firm had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. During the same quarter in the prior year, the business posted $4.23 EPS. The business’s revenue was up 9.1% compared to the same quarter last year. equities research analysts forecast that United Therapeutics will post 12.96 earnings per share for the current year.
In other news, CEO Martine A. Rothblatt sold 1,269 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $118.04, for a total transaction of $149,792.76. Following the completion of the transaction, the chief executive officer now owns 1,409 shares of the company’s stock, valued at $166,318.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,265 shares of the firm’s stock in a transaction on Thursday, October 19th. The shares were sold at an average price of $119.38, for a total transaction of $151,015.70. Following the transaction, the chief executive officer now directly owns 1,405 shares of the company’s stock, valued at approximately $167,728.90. The disclosure for this sale can be found here. In the last three months, insiders sold 17,036 shares of company stock valued at $2,077,449. 7.80% of the stock is owned by insiders.
Hedge funds have recently added to or reduced their stakes in the company. Quantbot Technologies LP raised its stake in shares of United Therapeutics by 537.3% during the third quarter. Quantbot Technologies LP now owns 975 shares of the biotechnology company’s stock valued at $114,000 after acquiring an additional 822 shares during the last quarter. Migdal Insurance & Financial Holdings Ltd. bought a new position in shares of United Therapeutics during the third quarter valued at $156,000. Toronto Dominion Bank raised its stake in shares of United Therapeutics by 244.7% during the third quarter. Toronto Dominion Bank now owns 1,903 shares of the biotechnology company’s stock valued at $223,000 after acquiring an additional 1,351 shares during the last quarter. Meiji Yasuda Asset Management Co Ltd. bought a new position in shares of United Therapeutics during the third quarter valued at $233,000. Finally, TLP Group LLC bought a new position in shares of United Therapeutics during the second quarter valued at $246,000. 99.99% of the stock is owned by hedge funds and other institutional investors.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).